Research programme: protein-protein interaction inhibitors - A2A Pharmaceutical/Biomea Healthcare
Alternative Names: A2A_O-01; AO 001; BMF-219 - A2A Pharmaceutical/Biomea Healthcare; Menin-MLL interaction inhibitors - A2A Pharmaceutical/Biomea Health; MLL-Menin small molecule - A2A Pharmaceutical/Biomea HealthcareLatest Information Update: 28 Feb 2025
At a glance
- Originator A2A Pharmaceuticals; Biomea Health
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein-protein interaction inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Leukaemia; Solid tumours
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for preclinical development in Leukaemia in USA
- 28 Feb 2025 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 30 Sep 2021 The US FDA approves IND application for protein-protein interaction inhibitors (A2A Pharmaceuticals pipeline, November 2021)